Brazil has more than 77 million people living with at least one chronic non-communicable disease.¹ Diabetes, hypertension, chronic kidney disease, and dyslipidemia form the core of this group, conditions that aren't cured, but managed. And the primary instrument of that management is the laboratory test: semi-annual HbA1c for the diabetic patient, quarterly creatinine for the CKD patient, annual lipid panel for the patient on treatment for dyslipidemia. The laboratory is, structurally, where chronic disease monitoring happens.
The problem is that the way most Brazilian laboratories deliver this data was not designed for longitudinal follow-up. It was designed for the point-in-time transaction.
Chronic disease requires data that most laboratories don't deliver
The clinical management of chronic disease is, by definition, longitudinal. The relevant therapeutic decision is rarely made from a single result. It is made from the trajectory. An HbA1c of 7.8% means something entirely different depending on whether it was 9.2% the previous semester (improvement under treatment) or 6.9% (deterioration requiring a change in management). The same logic applies to creatinine in the renal patient, LDL in the patient on statins, TSH in the patient on hypothyroidism treatment.
Guidelines from the Brazilian Diabetes Society, the Brazilian Society of Nephrology, and the Ministry of Health are explicit: periodic laboratory monitoring and trend analysis over time are essential components of the management protocol for each of these conditions.² But these guidelines implicitly assume that the patient's prior results are accessible, comparable, and interpretable alongside current results. In the day-to-day clinical practice of the Brazilian laboratory sector, this assumption frequently doesn't hold.
When a patient has tests performed at different laboratories over time, or at the same laboratory that has undergone system updates, prior results arrive in incompatible formats: different nomenclatures for the same analyte, reference ranges that vary between methodologies, units that don't correspond across periods. HbA1c recorded as "Glycated Hemoglobin" in one report and "HbA1c (IFCC)" in another is not automatically comparable. The IFCC methodology produces numerically distinct values from the NGSP/DCCT methodology, and the difference has direct diagnostic implications.³ A physician who doesn't identify this methodological variation may interpret a value change as clinical progression or improvement when, in reality, they are comparing incomparable methodologies.
The cost of fragmentation in chronic care
The operational and clinical consequences of longitudinal data fragmentation in chronic disease are documented. Population health management programs, such as Brazil's HIPERDIA program focused on monitoring hypertensive and diabetic patients, depend on serial biomarker analysis to identify patients with inadequate control, prioritize interventions, and evaluate the impact of therapeutic changes. When the data feeding these programs isn't comparable over time, analytical capacity is compromised at the source.
From a financial perspective, the lack of continuity in chronic patient laboratory data fuels a documented cycle of unnecessary testing. When a physician can't compare the current result with prior ones, because they are in different systems, with inconsistent nomenclatures or in non-integrable formats, the tendency is to re-order tests that have already been performed. Variations of just 10% in reference values between laboratories can generate unnecessary follow-up tests in up to 30% of cases.⁴ For a population of tens of millions of chronic patients in regular follow-up, this percentage represents an expressive volume of duplicate tests, extra consultations, and avoidable costs for the health system.
The laboratory that accompanies, not merely informs
The distinction between a laboratory that delivers a result and one that delivers contextualized clinical information is especially relevant in chronic care. The result reports the current value. The contextualized information compares that value against the patient's trajectory, signals relevant deviations, and gives the physician and the patient what they need for informed decisions.
This capability is not an add-on feature. It is what differentiates a laboratory from an analytical service that could be replaced by any competitor with a slightly lower price. When a laboratory can deliver to the physician a standardized, comparable timeline of HbA1c, creatinine, and microalbuminuria over three years, regardless of where each test was performed, it becomes a structural part of that patient's care process. It is no longer an interchangeable provider. It is a clinical partner with a track record.
Experiences in health systems with greater digital maturity show that integrating longitudinal laboratory data into chronic disease management platforms is associated with better clinical outcomes, greater protocol adherence, and reduction of avoidable hospitalizations.⁶ The underlying mechanism is consistent: when the physician has access to a reliable, comparable data trajectory, therapeutic decisions are more precise, management adjustments are made before deterioration becomes urgent, and the patient receives fewer unnecessary tests.
From transaction to follow-up
The transition from a transactional model, where each test is a standalone, independent delivery, to a longitudinal follow-up model doesn't require the laboratory to abandon its current operation. It requires investment in the layer that makes the results it already produces comparable over time: semantic harmonization of analytes, standardization of reference ranges by patient profile, and structuring of data into a timeline that follows the patient regardless of where or when each test was performed.
This is where OpenHealth Technologies stands out. The platform automatically correlates multiple data streams with rigorously validated logical layers of laboratory tests, unifying results from different sources, methods, and periods into a standardized, traceable, and clinically meaningful timeline. For laboratories serving populations of chronic patients, this means transforming each test performed into a point in a longitudinal narrative that has real clinical value, not only at the moment of release, but throughout the patient's entire care journey.